Trial intelligence / Profile preview

Phase 3 study of TAK-788 versus platinum-based chemotherapy as first-line treatment for EGFR exon 20 insertion-mutant non-small cell lung cancer

MOH_2020-06-11_008967Phase 3Not yet recruiting

Sponsor

Millennium Pharmaceuticals

Start

May 2020

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1